Gene Therapy for Sickle Cell Disease Likely Cost-Effective at

MONDAY, Jan. 22, 2024 -- Gene therapy for sickle cell disease (SCD) below $2 million is likely to be cost-effective, according to a study published online Jan. 23 in the Annals of Internal Medicine.Anirban Basu, Ph.D., from The Comparative Health...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news